Lymphovascular invasion is a significant risk factor for non-sentinel nodal metastasis in breast cancer patients with sentinel lymph node (SLN)-positive breast cancer: a cross-sectional study

According to the International Agency for Research on Cancer’s GLOBOCAN predictions of cancer incidence and death, as of 2020, there may be 2.3 million new instances of breast cancer globally (or 11.7% of all cases), overtaking lung cancer as the most frequent disease among women [1]. Breast cancer accounts for 24.5% of new cases and 15.5% of deaths in women globally, with figures of 19.9% and 9.9% in China, respectively [1]. The status of axillary lymph nodes is a crucial predictor of outcomes in early-stage breast cancer. Axillary lymph node dissection (ALND) has traditionally been the most effective method for assessing the extent of lymph node metastasis. However, ALND can lead to complications such as lymphedema, impaired arm mobility, and sensory disturbances. A 10-year follow-up revealed that ALND did not benefit patients with SLN micrometastases [2]. Sentinel lymph node biopsy (SLNB) offers an alternative to ALND, avoiding postoperative complications while maintaining diagnostic accuracy and prognostic information [3]. Currently, SLNB is the standard surgical technique for early-stage breast cancer patients with negative axillary lymph nodes. Research shows that the survival rates between the SLN + ALND group and the SLN group in patients with negative SLN are comparable [4].

Following the ACOSOG Z0011 study, ALND may be omitted for clinical T1-2 breast cancer patients with 1–2 positive SLNs, with radiotherapy planned after breast-conserving surgery [5]. Only 41% of patients with macrometastases SLNs are estimated to develop additional axillary involvement, and this proportion was only 18% in micrometastatic or isolated tumor cells SLNs [6], and the risk of non-SLN metastasis is approximately 28.6–34.9% [7]. Following the AMAROS study, there was no significant difference in 10-year axillary recurrence rate, Disease-free survival, or overall survival between axillary radiotherapy alone and ALND in clinical T1-2 breast cancer patients with 1–2 positive SLNs [8]. As of 2014, according to the American Society of Clinical Oncology (ASCO), patients with breast-conserving surgery and 1–2 SLN metastases who receive conventionally fractionated whole breast radiation are not recommended for ALND [9]. Since not all patients with positive SLNs will experience subsequent lymph node metastasis, many researchers have explored prediction models for non-SLN metastasis in such patients. Predictors of axillary lymph node metastasis include SLN metastasis size > 2 mm, extra-nodal involvement, and the proportion of sentinel lymph nodes affected [10]. Tumor multifocality, tumor size, and lymphovascular invasion have all been identified as separate predictors of axillary lymph node metastasis [11]. In addition, in patients with 1–2 positive SLNs, non-SLN metastasis is more common in the invasive lobular carcinoma group compared to invasive ductal carcinoma [12].

Studies have shown that tumor-associated lymphangiogenesis, angiogenesis, and lymphovascular invasion are prerequisites for tumor metastasis and are associated with lymph node metastasis [13]. The spread of cancer cells into blood vessels and lymphatic vessels is a critical early event in tumor metastasis. Lymphovascular invasion independently affects the prognosis of breast cancer patients [14].

While some studies have examined whether lymphovascular invasion is a separate risk factor for axillary lymph nodes, the results have been inconsistent. Furthermore, most studies are based on Western populations, and little research has focused on SLN-positive early-stage breast cancer patients. Therefore, our study aimed to evaluate the relationship between lymphovascular invasion and non-SLN metastases in Chinese breast cancer patients with SLN positivity.

The condition of the axillary lymph nodes significantly influences the treatment plan and prognosis for patients with primary breast cancer. SLNB has long been a safe and reliable method for evaluating axillary lymph node metastasis in clinically cN0 invasive breast cancer. If SLNB results confirm SLN metastasis, further ALND is performed. The findings from the IBCSG 23–01 and ACOSOG Z0011 trials suggest that ALND is not necessary for most patient populations with 1–2 SLN metastases who choose breast-conserving surgery and whole breast radiation therapy [4, 5]. More than 60 to 70% of patients with 1–2 SLN metastases do not require ALND or radiotherapy as regional treatment. In China, doctors often recommend ALND for patients with positive SLNs due to the low rate of breast-conserving surgery, unequal distribution of medical resources, and regional population differences [18]. However, patients prepared for breast-conserving surgery typically have smaller tumor sizes, hormone-receptor positivity, fewer positive SLNs, and an absence of lymphovascular invasion c. As our enrolled patients had no exclusion criteria related to breast surgery, the findings of this study apply to all surgical approaches. The results of the AMAROS study showed no difference in axillary recurrence rate, overall survival, and disease-free survival between ALND and axillary radiotherapy after a median follow-up of 10 years in cT1-2 breast cancer patients with 1–2 positive SLNs compared to each other [8]. However, considering the cost of treatment, adverse effects, and time cost, some cT1-2 breast cancer patients with 1–2 positive SLNs are not treated with radiotherapy as planned, especially in developing countries [19]. And more than 90% of cancer patients with radiotherapy would develop radiation dermatitis to a greater or lesser extent [20]. Can cT1-2 breast cancer patients with 1–2 positive SLNs without a radiotherapy plan be spared ALND, and what is their risk of axillary metastasis-related? Several previous studies found that 20% to 60% of patients were found to be free of non-SLN metastases after ALND. Therefore, these patients received unnecessary axillary therapy axillary therapy [21‐23]. In the study by Meng, L. et al. 448 (62.7%) patients with 1–2 positive SLNs showed no non-sentinel lymph node metastases on postoperative pathological sections [24]. In our study, only 126 (45%) of the SLN-positive patients were confirmed to have non-SLN metastasis after ALND. This indicates that the other 154 patients (55.0%) underwent unnecessary ALND. Among patients with just 1–2 SLN metastases, 81 patients (37.2%) exhibited non-SLN metastasis. aligning with previous studies by Straver, M. E, Lei Meng, and Weiqi Gao [7].

Therefore, it is increasingly important to accurately predict non-SLN metastasis. Several studies have been conducted by scholars in the past, but their results vary. Andersson Y. et al. showed that tumor size and histological grade were significantly correlated with non-SLN status [25]. In the literature report by X Y Wang and Lei Meng, the histological stage was an independent prognostic factor for non-SLN metastatic disease [26]. However, these conclusions do not align with the findings reported by Amina Maimaitiaili [27]. Siem A. Dingemans's study demonstrated that in patients with SLN metastases, tumor size > 2 cm was a predictor of non-SLN metastasis [28]. In our study, the number of SLN metastases, tumor size, and HER-2 expression were associated with non-SLN metastasis, consistent with previous research [10]. However, the histological stage did not demonstrate predictive value for non-SLN metastasis. The small sample size or the presence of false-negative and false-positive SLNs may be responsible. The success rate of SLN biopsy using double-tracer methods, such as fluorescent dye, was higher than that of single-tracer methods [29].

A retrospective cohort study including 602 patients revealed that factors such as age, menopausal status, tumor size, histologic grading, hormone receptor status, HER-2 status, and lymphovascular invasion did not act as independent predictors for non-SLN metastasis [30]. In the investigation conducted by Lale, A et al., clinicopathological aspects, namely HER-2 positivity, perineural invasion, SLN extranodal extension status, and a metastatic SLN diameter exceeding 10.5 mm, were found to be distinct risk factors for patients with breast cancer non-SLN metastasis. In univariate analysis, a notable increase in patients with lymphatic invasion and vascular invasion was observed; however, these associations were found to be non-significant in the multivariate analysis [31]. Furthermore, the study suggested a close association between non-SLN metastases and lymphovascular invasion [32]. It has been shown that vasculogenic mimicry in solid tumors is associated with a higher lymph node metastasis group and a poorer Nottingham prognostic index. The occurrence of vasculogenic mimicry and phosphorylation of Ephrin type-A receptor 2 are independent prognostic factors in breast cancer and are associated with disease aggressiveness and progression [33]. A meta-analysis, including 624 patients, confirmed a correlation between primary tumor lymphovascular infiltration and the methods used for its detection with non-SLN metastases [34]. Lymphovascular invasion emerged as an independent prognostic factor in the context of breast cancer. In accordance with the tumor metastasis cascade theory, the infiltration of tumor cells into blood vessels and entry into the circulation represent the early pivotal events in tumor metastasis [14]. Several studies have underscored the status of lymphovascular/vascular invasion as an independent prognostic factor for axillary metastasis from lymph nodes. However, pathological detection, it can be influenced by differing methods of sampling, film preparation, staining, and interpretation. The reported prevalence of a positive rate for lymphovascular/vascular invasion ranges from 21.2 to 47% [35]. This variation has some influence on the predictive value of vascular invasion for non-SLN metastases. In our study, out of 144 individuals (51.4%), all confirmed by IHC had a lymphovascular invasion. Univariate logistic regression analysis revealed a significant association between lymphovascular invasion and non-SLN metastasis (odds ratio [OR] = 6.11; 95% confidence interval [CI], 3.62–10.32), even after adjusting for variables such as age, menopausal status, number of positive SLNs, KI-67, HER-2, ER, and PR. The correlation between lymphovascular invasion and non-SLN metastases remained significant after multivariate regression analysis. Both multivariable logistic regression analysis and stratified analysis confirmed a correlation between lymphovascular invasion and non-SLN metastases. Hence, lymphovascular invasion stands as an independent risk component for non-SLN metastases.

To summarize, non-SLN metastases are associated with the number of SLN metastases, tumor size, HER-2 expression, and lymphovascular invasion. Patients with HER-2 positive status, more than 2 positive SLNs, tumor size exceeding 1 cm, or lymphovascular invasion are at an increased risk of developing non-SLN metastases. Lymphovascular invasion emerges as an independent risk factor for non-SLN metastasis in invasive breast cancer patients with 1–2 positive SLNs. Lymphovascular invasion not only aids in surgical decision-making but also offers guidance for adjuvant treatment options. Patients with 1 or 2 SLNs testing positive but not receiving ALND or axillary radiotherapy face the risk of insufficient adjuvant treatment, particularly if they exhibit lymphovascular invasion, which raises the possibility of metastasis. In principle, the decision to administer adjuvant chemotherapy or radiotherapy can be informed by the presence or absence of vascular infiltration. In clinical practice, tailored strategies should be developed based on the clinicopathological characteristics of individual patients to prevent complications stemming from transitional axillary treatment. In cases involving lymphovascular invasion, the selection of axillary local treatment strategies should be made with great care to avoid inadequate treatment.

It is important to acknowledge some potential limitations of this study. Firstly, a single-tracer method was utilized for sentinel lymph node biopsy, potentially leading to false-negative or false-positive sentinel lymph nodes. In this study, methylene blue dye was employed for subareolar injection, which results in higher identification rates when methylene blue dye alone is used as a tracer [36]. However, subareolar injection complicates the visualization of internal mammary lymph nodes. Internal mammary lymph nodes, a significant metastatic route second only to axillary lymph nodes, serve as an independent prognostic factor for breast cancer [37]. Our study’s use of subareolar injections may have resulted in the omission of some internal mammary lymph node data. Moreover, the study primarily included patients with outer quadrant breast cancer, and patients with inner quadrant breast cancer were underrepresented. Consequently, these variables were not included in the study. The metastasis of internal mammary sentinel lymph nodes in patients with inner quadrant breast cancer could not be adequately assessed in this study. Our study divided the histological grading into high and low groups according to aggressiveness. It could not assess the difference between histological grading 1 and 2 adequately. Patient follow-up was not conducted, preventing a comparison of patient prognoses.